Статья
СОВРЕМЕННЫЙ ВЗГЛЯД НА РОЛЬ АСЕПТИЧЕСКОГО ВОСПАЛЕНИЯ ЖИРОВОЙ ТКАНИ В ГЕНЕЗЕ ОЖИРЕНИЯ И МЕТАБОЛИЧЕСКОГО СИНДРОМА
За два последних десятилетия коренным образом изменились взгляды на роль жировой ткани в метаболическом и энергетическом обмене. Поступают все новые и новые свидетельства о продукции жировой тканью целого класса биологически активных веществ, так называемых адипоцитокинов, общими свойствами которых являются участие в регуляции обменных процессов на местном или системном уровне, повышение или снижение чувствительности тканей к инсулину, а также провоспалительное или противовоспалительное действие. Анализируя взаимосвязь и взаимовлияние абдоминального ожирения, асептического воспаления жировой ткани и инсулинорезистентности, следует подчеркнуть, что данные процессы действуют по принципу взаимоусиления, формируя порочный круг. Более глубокому пониманию участия адипокинов и цитокинов в развитии ожирения и метаболического синдрома способствовало бы выяснение их биологической роли
1. World Health Organization. Fact sheets. — 2013.. — URL: http://www.who.int/mediacentre/factsheets/.
2. Драпкина О.М., Корнеева О.Н., Палаткина Л.О. Адипокины и сердечно-сосудистые заболевания: патогенетические параллели и терапевтические перспективы // Артериальная гипертензия. — 2011. — Т. 17, № 3. — С. 203–208. / Drapkina O.M., orneeva O.N., Palatkina L.O. Adipokines and cardiovascular diseases: pathogenic parallels and therapeutic perspectives // Arte-rial Hypertension. — 2011. — Vol. 17, № 3. — P. 203–208.
3. Apovian C.M., Gokce N. Obesity and cardiovascular disease // Circulation. — 2012. — Vol. 125, № 9. — P. 1178–1182.
4. Драпкина О.М., Чапаркина С.О. Взаимосвязь метаболического синдрома, асептического воспаления и дисфункции эндотелия // Рос. мед. вести. — 2007. — Т. 12, № 3. — C. 67–76. / Drapkina O.M., Chaparkina S.O. Association of metabolic syndrome, aseptic inlammation and endothelial dysfunction // Russian Medical News. — 2007. — Vol. 12, № 3. — P. 67–76.
5. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss // J. Am. Coll. Cardiol. — 2009. — Vol. 53, № 21. — P. 1925–1932.
6. Gregor M.F., Hotamisligil G.S. Inlammatory mechanisms in obesity // Annu. Rev. Immunol. — 2011. — Vol. 29. — P. 415–445.
7. Sun K., Kusminski C.M., Scherer P.E. Adipose tissue remodeling and obesity // J. Clin. Invest. 2011. — Vol. 121, № 6. — P. 2094–2101.
8. Cancello R., Henegar C., Viguerie N. et al. Reduction of macrophage iniltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss // Diabetes. — 2005. — Vol. 54, № 8. — P. 2277–2286.
9. Huber J., Kiefer F.W., Zeyda M. et al. CC chemokine and CC chemokine receptor proiles in visceral and subcutaneous adipose tissue are altered in human obesity // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93, № 8. — P. 3215–3221.
10. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Jr. Obesity is associated with macrophage accumulation in adipose tissue // J. Clin. Invest. — 2003. — Vol. 112, № 12. — P. 1796–1808.
11. Nishimura S., Manabe I., Nagasaki M. et al. In vivo imaging in mice reveals local cell dynamics and inlammation in obese adipose tissue // J. Clin. Invest. — 2008. — Vol. 118, № 2. — P. 710–721.
12. Christiansen T., Paulsen S.K., Bruun J.M., Pedersen S.B., Richelsen B. Exercise-training versus diet- induced weight-loss on metabolic risk factors and inlammatory markers in obese subjects. A 12-week randomized intervention-study // Am. J. Physiol. Endocrinol. Metab. — 2010. — Vol. 298, № 4. — P. 824–831.
13. Cancello R., Tordjman J., Poitou C. et al. Increased iniltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity // Diabetes. — 2006. — Vol. 55, № 6. — P. 1554–1561.
14. Bastard J.P., Maachi M., Lagathu C. et al. Recent advances in the relationship between obesity, inlammation, and insulin resistance // Eur. Cytokine Netw. — 2006. — Vol. 17, № 1. — P. 4–12.
15. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization // J. Clin. Invest. — 2007. — Vol. 117, № 1. — P. 175–184.
16. Lumeng C.N., Deyoung S.M., Bodzin J.L., Saltiel A.R. Increased inlammatory properties of adipose tissue macrophages recruited during diet- induced obesity. Diabetes. — 2007. — Vol. 56, № 1. — P. 16–23.
17. Ruan H., Lodisch H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis faktor-alpha // Cytokine Growth Factor Rev. — 2003. — Vol. 14, № 5. — P. 447–455.
18. Hotamisligil G.S. Inlammatory pathways and insulin action // Int. J. Obes. Relat. Metab. Disord. — 2003. — Vol. 27, suppl. 3. — P. 553–555.
19. Fernandez-Real J.M., Ricart W. Insulin resistance and chronic cardiovascular inlammatory syndrome // Endocr. Rev. — 2003. — Vol. 24, № 3. — P. 278–301.
20. Ruan H., Miles P.D., Ladd C. M. Proiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor — alpha: implications for insulin resistance // Diabetes. — 2002. — Vol. 51, № 11. — P. 3176–3188.
21. Bahceci M., Gokalp D., Bahceci S. et al. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inlammation in adults? // J. Endocrinol. Invest. — 2007. — Vol. 30, № 3. — Р. 210–214.
22. De Alvaro C., Teruel T., Hernandez R., Lorenzo M. Tumor necrosis factor alpha produced insulin resistance in sceletal muscle by activation of inhibitor kappaB-kinase in ap38 MARK-dependant manner // J. Biol. Chem. — 2004. — Vol. 279, № 17. — P. 17070–17078.
23. Vozarova B., Weyer C., Hanson K., Tataranni P.A., Bogardus C., Pratley R.E. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion // Obes. Res. — 2001. — Vol. 9, № 7. — P. 414–417.
24. Carey A.L., Bruce C.R., Sacchetti M. et al. Interleukin-6 and tumor necrosis factor — alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness // Diabetologia. — 2004. — Vol. 47, № 6. — P. 1029–1037.
25. Cai D., Yuan M., Frantz D.F. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-βand NF-кB // Nat. Med. — 2005. — Vol. 11, № 2. — P. 183–190.
26. Febbraio M.A., Pedersen B.K. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles // FASEB J. — 2002. — Vol. 16, № 11. — P. 1335–1347.
27. Zhu W., Cheng K.K., Vanhoutte P.M., Lam K.S., Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond). — 2008. — Vol. 114, № 5. — P. 361–374.
28. Fantuzzi G. Adipose tissue, adipokines, and inlammation // J. Allergy Clin. Immunol. — 2005. — Vol. 115, № 5. — P. 911–919.
29. Aprahamian T.R., Sam F. Adiponectin in cardiovascular inlammation and obesity // Int. J. Inlam. — 2011. — Vol. 31, № 2. — P. 167–73.
30. Zhang H., Park Y., Zhang C. Coronary and aortic endothelial function affected by feedback between adiponectin and tumor necrosis factor alpha in type 2 diabetic mice // Arterioscler. Thromb. Vasc. Biol. — 2010. — Vol. 30, № 11. — P. 2156–2163.
31. Park P.H., McMullen M.R., Huang H., Thakur V., Nagy L.E. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production // J. Biol. Chem. — 2007. — Vol. 282, № 30. — P. 21695–21703.
32. Lovren F., Pan Y., Quan A. et al. Adiponectin primes human monocytes into alternative anti-inlammatory M2 macrophages // Am. J. Physiol. Heart Circ. Physiol. — 2010. — Vol. 299, № 3. — P. 656–663.
33. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., Christian J.A., Spurlock M.E. Adiponectin differentially regulates cytokines in porcine macrophages // Biochem. Biophys. Res. Commun. 2004. — Vol. 316, № 3. — P. 924–929.
34. Yamaguchi N., Argueta J.G., Masuhiro Y. et al. Adiponectin inhibits Toll-like receptor family-induced signalling // FEBS Lett. — 2005. — Vol. 579, № 30. — P. 6821–6826.
35. Devaraj S., Torok N., Dasu M.R., Samols D., Jialal I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-tissue-vascular loop // Arterioscler. Thromb. Vasc. Biol. — 2008. — Vol. 28, № 7. — P. 1368–1374.
36. Xu Y., Zhang C., Wang N. et al. Adiponectin inhibits lymphotoxin-beta receptor-mediated NF-KappaB signaling in human umbilical vein endothelial cells // Biochem. Biophys. Res. Commun. — 2010. — Vol. 404, № 4. — P. 1060–1064.
37. Jin С., Henao-Mejia J., Flavell R.A. Innate immune receptors: key regulators of metabolic disease progression // Cell Metab. — 2013. — Vol. 17, № 6. — P. 873–82.
38. Lee J. Adipose tissue macrophages in the development of obesity-induced inlammation, insulin resistance and type 2 diabetes // Arch. Pharm. Res. — 2013. — Vol. 36, № 2. — P. 208–222.
39. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inlammation // Circulation. —2005. — Vol. 111, № 11. — P. 1448–54.
40. Dandona P., Ghanim H., Chaudhuri A. et al. Macronutrient intake induces oxidative and inlammatory stress: potential relevance to atherosclerosis and insulin resistance // Exp. Mol. Med. — 2010. — Vol. 42, № 4. — P. 245–253.
41. Gaesser G.A., Angadi S.S., Ryan D.M. et al. Lifestyle measures to reduce inlammation // Am. J. Lifestyle Med. — 2012. — Vol. 6, № 1. — P. 4–13.
42. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inlammation and metabolic syndrome // Mol. Cell. Endocrinol. — 2010. — Vol. 314, № 1. — P. 1–16.
43. Kusminski C.M., McTernan P.G., Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes // Clin. Sci. (Lond). — 2005. — Vol. 109, № 3. — P. 243–256.
44. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inlammation and immunity // Nat. Rev. Immunol. — 2006. — Vol. 6, № 10. — P. 772–83.
45. Kusminski C.M., Scherer P.E. The road from discovery to clinic: adiponectin as a biomarker of metabolic status // Clin. Pharmacol. Ther. — 2009. — Vol. 86, № 8. — P. 592–595.
46. Jae S.Y., Fernhall B., Heffernan K.S. et al. Effects of life-style modiications on C-reactive protein: contribution of weight loss and improved aerobic capacity // Metab. Clin. Experiment. — 2006. — Vol. 55, № 6. — P. 825–831.
47. Luo N., Liu J., Hong Chung B. et al. Macrophage adiponectin expression improves insulin sensitivity and protects against inlammation and atherosclerosis // Diabetes. — 2010. — Vol. 59, № 4. — P. 791–799.
48. Kim J.Y., van de Wall E., Laplante M. et al. Obesityassociated improvements in metabolic proile through expansion of adipose tissue // J. Clin. Invest. — 2007. — Vol. 117, № 9. — P. 2621–2637.
49. Saunders T.J., Palombella A., McGuire K. A. et al. Acute exercise increases adiponectin levels in abdominally obese men // J. Nutrition Metab. — 2012. — Vol. 2012. — ID: 148729.
50. Racil G., Ben Ounis O., Hammouda O. et al. Effects of high vs. moderate exercise intensity during interval training on lipids and adiponectin levels in obese young females // Eur. J. Appl. Physiol. — 2013. — Vol. 113, № 10. — Р. 2531–2540.
51. Березина A.B., Беляева О.Д., Беркович Е.А. и др. Качество жизни у больных абдоминальным ожирением при снижении веса тела с помощью диеты и физических тренировок // Профилакт. клинич. мед. — 2011. — Т. 1 (39), № 2. — С. 23–30. / Berezina A.V., Belyaeva O.D., Berkovich E.A. et al. Quality of life in patients with abdominal obesity while weight loss with help of diet and physical exercise // Preventive and Clinical Medicine. — 2011. — Vol. 1 (39), № 2. — P. 23–30.
52. Березина A.B. Физическая активность и факторы риска сердечно-сосудистых заболеваний у больных абдоминальным ожирением // Вестн. Рос. Академии естественных наук. —2011. — Т. 15, № 3. — С. 89–94. / Berezina A.V. Physical activity and cardiovascular risk factors in patients with abdominal obesity // Herald of the Russian Academy of Natural Sciences. — 2011. — Vol. 15, № 3. — P. 89–94.
53. Hulver M.W., Zheng D., Tanner C.J. et al. Adiponectin is not altered with exercise training despite enhanced insulin action // Am. С. Physiol. Endocrinol. Metab. — 2002. — Vol. 283, № 4. — P. 861–865.
54. Ryan A.S., Nicklas B.J., Berman D.M., Elahi D. Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women // Int. J. Obes. Relat. Metab. Disord. — 2003. — Vol. 27, № 9. — P. 1066–1071.
55. Yokoyama H., Emoto M., Araki T. et al. Effect of aerobic exercise on plasma adiponectin levels and insulin resistance in type 2 diabetes // Diabetes Care. — 2004. — Vol. 27, № 7. — P. 1756–1758.
56. Nassis G.P., Papantakou K., Skenderi K. et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inlammatory markers in overweight and obese girls // Metabolism. — 2005. — Vol. 54, № 11. — P. 1472–1479.
57. Moghadasi M., Mohebbi H., Rahmani-Nia F. et al. Effects of short-term lifestyle activity modiication on adiponectin mRNA expression and plasma concentrations // Eur. J. Sport Sci. — 2013. — Vol. 13, № 4. — P. 378–385.